Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Improved therapy of myotonia with the lidocaine derivative tocainide.

Literature DB >> 6154787

Improved therapy of myotonia with the lidocaine derivative tocainide.

R Rüdel, R Dengler, K Ricker, A Haass, W Emser.

Abstract

The antimyotonic effect of the antiarrhythmic drug tocainide was tested in 14 patients. With 1200 to 1600 mg/d all patients reported good improvement. This was substantiated by objective tests. Only four patients noticed minor side effects.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1980 PMID： 6154787 DOI： 10.1007/BF00313157

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

6 in total

1. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo.

Authors: T L Munsat
Journal: Neurology Date: 1967-04 Impact factor: 9.910

2. Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin.

Authors: K L Birnberger; R Rüdel; A Struppler
Journal: J Neurol Date: 1975-09-01 Impact factor: 4.849

3. Effects of tocainide on normal and myotonic mammalian skeletal muscle.

Authors: R Dengler; R Rüdel
Journal: Arzneimittelforschung Date: 1979

4. Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

Authors: K Ricker; A Haass; R Rüdel; R Böhlen; H G Mertens
Journal: J Neurol Neurosurg Psychiatry Date: 1980-03 Impact factor: 10.154

5. Clinical electrophysiologic effects of tocainide.

Authors: J L Anderson; J W Mason; R A Winkle; P J Meffin; R E Fowles; L Peters; D C Harrison
Journal: Circulation Date: 1978-04 Impact factor: 29.690

6. Long-term tocainide therapy for ventricular arrhythmias.

Authors: R A Winkle; P J Meffin; D C Harrison
Journal: Circulation Date: 1978-05 Impact factor: 29.690

6 in total

15 in total

1. Neuromyotonia in hereditary motor neuropathy.

Authors: A F Hahn; A W Parkes; C F Bolton; S A Stewart
Journal: J Neurol Neurosurg Psychiatry Date: 1991-03 Impact factor: 10.154

2. Inactivation of human sodium channels and the effect of tocainide.

Authors: B Fakler; J P Ruppersberg; W Spittelmeister; R Rüdel
Journal: Pflugers Arch Date: 1990-03 Impact factor: 3.657

3. The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation.

Authors: A DeLuca; T Pröbstle; H Brinkmeier; R Rüdel
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1991-11 Impact factor: 3.000

Improved therapy of myotonia with the lidocaine derivative tocainide.

1. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo.

2. Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin.

3. Effects of tocainide on normal and myotonic mammalian skeletal muscle.

4. Successuful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide.

5. Clinical electrophysiologic effects of tocainide.

6. Long-term tocainide therapy for ventricular arrhythmias.

1. Neuromyotonia in hereditary motor neuropathy.

2. Inactivation of human sodium channels and the effect of tocainide.

3. The different use dependences of tocainide and benzocaine are correlated with different effects on sodium channel inactivation.

4. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

5. Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel.

6. Myotonia congenita and myotonic dystrophy: surveillance and management.

Review 7. Channelopathies of skeletal muscle excitability.

8. Mexiletine for treatment of myotonia: a trial triumph for rare disease networks.

Review 9. Sodium channelopathies of skeletal muscle result from gain or loss of function.

10. Novel CLCN1 mutations and clinical features of Korean patients with myotonia congenita.